This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Healthcare Trends to Ride for Longevity
by Andrew Rocco
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Take the Zacks Approach to Beat the Market: Shopify, Brambles, McDonald's in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
by Zacks Equity Research
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study
by Zacks Equity Research
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
by Zacks Equity Research
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Don't Ignore the Momentum in These 3 Stocks
by Derek Lewis
Momentum investing is centered around targeting stocks displaying outperformance. And when you add in the Zacks Rank, the strategy can become even more potent.
Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Beat the Market Like Zacks: Novo Nordisk, Microsoft, Clorox in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
by Zacks Equity Research
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Novo Nordisk and Nutrien have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Novo Nordisk and Nutrien are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Novo Nordisk A/S (NVO)
by Bryan Hayes
Stellar earnings and sales growth has this pharmaceutical stock trading near all-time highs.
Novo Nordisk (NVO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Novo Nordisk (NVO) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Buy These 4 Low-Beta Stocks to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.
Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More
by Kinjel Shah
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.
Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Zacks Investment Ideas feature highlights: Novo Nordisk and Clearfield
by Zacks Equity Research
Novo Nordisk and Clearfield have been highlighted in this Investment Ideas article.